QCM Cayman’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

QCM Cayman’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-2,438	Closed	-$219K	–	95
2022 Q1	$219K	Buy	+2,438	New	+$225K	0.96%	50
2021 Q1	–	Sell	-2,965	Closed	-$417K	–	321
2020 Q4	$417K	Buy	+2,965	New	+$380K	0.43%	59
2020 Q2	–	Sell	-2,906	Closed	-$225K	–	143
2020 Q1	$225K	Buy	+2,906	New	+$257K	38.53%	1
2016 Q4	–	Sell	-3,986	Closed	-$264K	–	261
2016 Q3	$264K	Buy	+3,986	New	+$247K	0.29%	95

Other funds holding XBI

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

QCM Cayman's XBI Position: Q2 2022 in Review

QCM Cayman sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2022, closing a stake of 2,438 shares — an estimated $219K sold.

QCM Cayman first reported a position in XBI in Q3 2016 and held it in 4 quarters. The position peaked at $417K in Q4 2020. 704 funds tracked by Wall St. Rank hold XBI as of Q2 2022.

QCM Cayman reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2022 after selling out during the quarter.
QCM Cayman sold 2,438 State Street SPDR S&P Biotech ETF shares in Q2 2022, an estimated $219K.
QCM Cayman first reported a position in State Street SPDR S&P Biotech ETF in Q3 2016 and held it in 4 quarters.
QCM Cayman's State Street SPDR S&P Biotech ETF position peaked at $417K in Q4 2020.
704 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2022.

Based on QCM Cayman's 13F filing for Q2 2022, filed 27 Jul 2022.